arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

AbCellera Biologics Inc.

ABCL

$11.12 ▼ -1.16 (-9.49%) at close

8 Visible periods

27 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

AbCellera Biologics Inc. faces fundamental challenges with weakness in Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.3B

Dividend Yield —

Revenue Growth 160.6% ↗

Op. Margin -289.0%

ROIC -18.5% ↗

FCF / Share $-0.58 ↗

Trailing P/E —

Price / Book 3.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$75.13M

↑ +160.6% —

Net Income Profit after all expenses

$-146.41M

↑ +10.1% —

Operating Margin Operating profit as % of sales

-289.0%

↓ -747.9% 0th

FCF / Share Free cash flow per share

$-0.58

↑ +8.3% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↓

Returns

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue Growth YoY (%)	160.6% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1907%)	-24.2% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-402%)	-92.2% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1252%)	29.4% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+267%)	60.9% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+662%)	1907.9% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+23748%)	—	—
EPS Growth YoY (%)	10.9% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	-7.8% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	N/M	0.0% Caution Caution Year-over-year change in earnings per share Optimal: > 10%	5.7% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	N/M	—	—
Net Income Growth YoY (%)	10.1% Fair ↑ Fair Improving Year-over-year change in net income	-11.2% Weak ↓ Weak Declining Year-over-year change in net income	N/M	3.3% Caution Caution Year-over-year change in net income	29.1% Excellent Excellent Year-over-year change in net income	N/M	—	—
FCF Growth YoY (%)	8.3% Fair ↑ Fair Improving Year-over-year change in free cash flow	-52.0% Weak ↓ Weak Declining Year-over-year change in free cash flow	N/M	7.4% Fair Fair Year-over-year change in free cash flow	725.5% Excellent Excellent Year-over-year change in free cash flow	N/M	—	—
Revenue CAGR 3Y (%)	-46.3% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	-57.5% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	-45.4% Weak Weak Compound annual revenue growth over 3 years	247.1% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	-20.3% Weak Weak Compound annual revenue growth over 5 years	19.9% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Operating Margin (%) (%)	-289.0% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2027%)	—	—	44.6% Excellent ↑ Excellent Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+197%)	54.5% Excellent ↑ Excellent Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+263%)	66.9% Excellent Excellent Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+346%)	-35.5% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-336%)	—
Effective Tax Rate (%) (%)	17.6% Good ↓ Good Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	18.7% Good ↓ Good Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	15.9% Good ↓ Good Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	33.7% Weak ↑ Weak Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	30.0% Caution Caution Actual taxes paid relative to pre-tax income Optimal: 15-25%	24.7% Fair Fair Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
Profit Margin (%) (%)	-194.9% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1724%)	—	-385.0% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3308%)	32.7% Excellent ↑ Excellent Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+172%)	40.9% Excellent ↑ Excellent Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+241%)	51.0% Excellent Excellent Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+325%)	-19.0% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-259%)	—
FCF Margin (%) (%)	-231.7% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	—	-317.7% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	42.6% Excellent ↑ Excellent Improving Free cash flow as a percentage of revenue Optimal: > 10%	49.6% Excellent ↑ Excellent Improving Free cash flow as a percentage of revenue Optimal: > 10%	5.6% Caution Caution Free cash flow as a percentage of revenue Optimal: > 10%	-11.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	1.19x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.15x Fair → Fair Stable Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.30x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	1.21x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.11x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.59x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Return on Invested Capital (%)	-18.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-24.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-17.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	11.6% Good ↑ Good Improving Return earned on debt + equity capital invested Optimal: > 10%	14.0% Good ↑ Good Improving Return earned on debt + equity capital invested Optimal: > 10%	14.2% Good Good Return earned on debt + equity capital invested Optimal: > 10%	-31.7% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-16.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-23.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-15.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	14.1% Good ↓ Good Declining Operating profit relative to total assets Optimal: > 10%	15.5% Excellent Excellent Operating profit relative to total assets Optimal: > 10%	15.5% Excellent Excellent Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-15.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-201%)	-15.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-203%)	-12.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-185%)	12.9% Fair ↑ Fair Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-14%)	15.0% Fair ↑ Fair Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: At sector avg	14.3% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: At sector avg	-21.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-244%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Net Debt (USD)	$-128.51M	$-156.32M	$-133.32M	$-386.54M	$-476.14M	$-594.12M	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue per Share (USD)	$0.25	$0.10	$0.13	$1.70	$1.36	$1.46	$0.08	—
Basic EPS, GAAP (USD)	$-0.49	$-0.55	$-0.51	$0.56	$0.56	$0.53	$-0.01	—
Free Cash Flow per Share (USD)	$-0.58	$-0.64	$-0.42	$0.73	$0.67	$0.08	$-0.01	—
Book Value per Share (USD)	$3.22	$3.57	$3.96	$4.30	$3.62	$3.08	$0.07	—
Tangible Book Value per Share (USD)	$2.93	$3.27	$3.38	$3.67	$2.93	$2.54	$0.07	—
Basic Weighted Avg Shares (shares)	298.71M	294.33M	289.17M	285.06M	275.76M	159.20M	151.33M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Working Capital (USD)	$663.92M	$674.76M	$752.97M	$907.17M	$809.12M	$709.84M	—	—
Total Equity (USD)	$966.90M	$1.06B	$1.15B	$1.23B	$1.03B	$830.51M	$10.25M	$11.61M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Sales/Revenue/Turnover (USD)	$75.13M	$28.83M	$38.02M	$485.42M	$375.20M	$233.16M	$11.61M	—
Depreciation Expense (USD)	$18.44M	$12.54M	$12.76M	$8.95M	$4.40M	$2.32M	$1.60M	—
Net Income, GAAP (USD)	$-146.41M	$-162.86M	$-146.40M	$158.52M	$153.46M	$118.92M	$-2.21M	—
Operating Cash Flow (USD)	$-131.29M	$-108.56M	$-43.88M	$277.36M	$244.58M	$22.69M	$2.69M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 8 years · 28 quarters

AbCellera Biologics Inc.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ABCL with peers